miRview™ mets utilizes proprietary technology developed by Rosetta Genomics to identify 25 different tumor types, including, but not limited to, tumors with the following tissue origins: colon, liver, breast, kidney, lung, ovary, pancreas, prostate, and testis. This technology includes protocols for the extraction of microRNA from formalin-fixed paraffin-embedded (FFPE) tissue samples and quantification of the relative amounts of various microRNA biomarkers using quantitative real-time polymerase chain reaction (qRT-PCR) technology. The test also uses a proprietary classifier to assign a primary site to the cancer sample based on the microRNA expression in the tumor.

miRview™ mets is the product of two years of research with hundreds of tumor samples. In the first phase of development, more than 100 tumor samples were studied by high-throughput molecular profiling¹. Molecular profiling using microRNA microarrays was used to identify the molecular markers for the tumor types studied¹. In the second phase, the microRNA markers were validated and a diagnostic assay defined using sensitive and specific proprietary qRT-PCR technology¹.

The performance of the miRview™ mets assay was determined in an independent, blinded test. In the majority of cases, miRview™ mets returned a single tissue prediction with 90% sensitivity and 99% specificity2.

While many of the cancer tests currently available are largely qualitative and subjective, the measurement of microRNA expression levels in tissue samples offers a quantitative, objective diagnosis. Proprietary technologies enable microRNA profiling with high sensitivity and specificity (for miRview™ mets, these values have been shown to be 90% and 99%, respectively)². In addition, microRNAs are stable markers in many body fluids and tissue samples, making them an ideal platform for molecular diagnostics.

Download Product Profile

1. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin.
   Nat Biotechnol. 2008;26(4):462-469.
2. Data on file, Rosetta Genomics.